Autonomix Medical (Nasdaq:AMIX) announced today that it advanced its proprietary sensing catheter through a final design ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI and digital twins are helping clinical trials become more efficient, patient-centric, and capable of supporting innovative study ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, discusses whether recent trial design rejections signal a broader shift in FDA expectations or simply reflect changes in individual ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, ...

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption ("IDE"), and if ap ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Study Overview: Celgene Corporation is conducting a clinical ...

Anxiety symptoms among U.S. adults, even during the COVID-19 pandemic, appear to have remained stable, according to a massive ...

Discover DiaMedica Therapeutics' Q2 2025 earnings call highlights: promising preeclampsia trial results, progress in stroke programs & a $60M extended ...

Blinking your eyelids is not a simple matter of up and down. Muscular contractions occur in segments that control the ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.